+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Scar - Pipeline Review, H1 2019

  • ID: 4760856
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 82 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Abzena Plc
  • BirchBioMed Inc
  • Kringle Pharma Inc
  • Moerae Matrix Inc
  • Pharmaxis Ltd
  • Phio Pharmaceuticals Corp
  • MORE
Scar - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2019, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights

This latest pipeline guide Scar - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 9 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from 's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abzena Plc
  • BirchBioMed Inc
  • Kringle Pharma Inc
  • Moerae Matrix Inc
  • Pharmaxis Ltd
  • Phio Pharmaceuticals Corp
  • MORE
Introduction

Report Coverage

Scar - Overview

Scar - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Scar - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Scar - Companies Involved in Therapeutics Development

Abzena Plc

BirchBioMed Inc

Cotinga Pharmaceuticals Inc

Kringle Pharma Inc

Moerae Matrix Inc

Pharmaxis Ltd

Phio Pharmaceuticals Corp

Promore Pharma AB

Resolys Bio Inc

Synedgen Inc

Vascular BioSciences

Scar - Drug Profiles

albuterol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-slo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Evitar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBM-5712 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

magacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMI-0100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Fibrotic Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharide for Wounds and Scars - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SOX-9 for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Scar - Dormant Projects

Scar - Discontinued Products

Scar - Product Development Milestones

Featured News & Press Releases

Feb 28, 2019: First patient enrolled in BirchBioMed's study investigating FS2 for the treatment of scars

Feb 01, 2019: Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study

Oct 23, 2018: Promore Pharma has had a successful meeting with the FDA regarding PXL01

Sep 03, 2018: Promore Pharma plans to expand indications of therapeutic peptide PXL01 in the field of dermal scarring

May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO

Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug

Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing

Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US

Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America

Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017

May 17, 2017: Promore Pharma files phase III clinical trial application in India

Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug

Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Scar, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Scar - Pipeline by Abzena Plc, H1 2019

Scar - Pipeline by BirchBioMed Inc, H1 2019

Scar - Pipeline by Cotinga Pharmaceuticals Inc, H1 2019

Scar - Pipeline by Kringle Pharma Inc, H1 2019

Scar - Pipeline by Moerae Matrix Inc, H1 2019

Scar - Pipeline by Pharmaxis Ltd, H1 2019

Scar - Pipeline by Phio Pharmaceuticals Corp, H1 2019

Scar - Pipeline by Promore Pharma AB, H1 2019

Scar - Pipeline by Resolys Bio Inc, H1 2019

Scar - Pipeline by Synedgen Inc, H1 2019

Scar - Pipeline by Vascular BioSciences, H1 2019

Scar - Dormant Projects, H1 2019

Scar - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Scar, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abzena Plc
  • BirchBioMed Inc
  • Cotinga Pharmaceuticals Inc
  • Kringle Pharma Inc
  • Moerae Matrix Inc
  • Pharmaxis Ltd
  • Phio Pharmaceuticals Corp
  • Promore Pharma AB
  • Resolys Bio Inc
  • Synedgen Inc
  • Vascular BioSciences
Note: Product cover images may vary from those shown
Adroll
adroll